Skip to content
SWR_Series-B-Announcement_Website

Sware Raises $6M to Accelerate Life Sciences Innovation by Automating FDA-Mandated Software Validation

BOX Partner_1920x1080_Life Sciences_Sware_web
ANNOUNCEMENT

Sware Selected as Box’s 2025 Life Sciences Partner of the Year

September 10, 2025 9:00 AM EST  |  Boston  

We're thrilled to share exciting news that showcases the impact of our work and the strength of our partnerships. Sware has been named Box’s 2025 Life Sciences Partner of the Year! This recognition reflects our exceptional contributions, customer impact, and commitment to excellence within the Box partner ecosystem.

Through our strategic partnership with Box, we are revolutionizing GxP validation for life sciences organizations by providing access to our industry-leading Res_Q platform. Together, we’re delivering best-in-class solutions that modernize validation while maintaining the highest standards of regulatory compliance.

"As our industry continues to modernize its approach to quality and technology, we have a unique opportunity to lead by example," said Chris Jay Jurkiewicz, Head of Global Growth & Partnerships. "This award not only highlights our technological innovation, but our commitment to building partnerships that create meaningful impact for life sciences companies."

This award reinforces our belief that better compliance is possible through collaboration, innovation, and purpose-built technology and signals growing momentum toward our mission to reduce the burden of validation, eliminate inefficiencies, and accelerate delivery of regulated products to market. 

This achievement would not be possible without the dedication, passion, and expertise of our entire team. We thank you for your ongoing contributions as we continue to build the future of compliance technology.

— Ellen Reilly, CEO

Become a trusted partner

Nate_Mcbride
Nate_Mcbride
Nate_Mcbride

Nathan McBride
Senior Vice President, IT
Xilio Therapeutics

Nathan McBride
Senior Vice President, IT
Xilio Therapeutics

Nathan McBride
Senior Vice President, IT
Xilio Therapeutics